Board, Advisers, Consultants, and Collaborators (to be completed soon).
Mahmood Moshiri BS, MD, CPATH, APATH, RNCP,ROHP, DTNH, FICN

Dr. Moshiri co-founded many private and public companies including Next Pharma Inc. (valuated $169 Million), Richmond Biotechnology Inc., Panacea Global Inc. (PGI), Proteus Imaging Canada Inc., Panacea Laboratories Canada Inc., and Panacea Pharma Inc. In 2009, he founded Panacea Global Inc., a publicly traded company on OTC-BB-NASDAQ, with a Market Cap of $90 Million, and served as President, CEO, CSO, and Chairman until 2016. Dr. Moshiri has extensive experience in teaching and practicing medicine and performing clinical research focused on cancer pathology, hybridoma and ELISA kit manufacturing, national and international marketing and commercialization of Medical Devices (receiving Purchase Order more than $1.3 B). He has published and lectured extensively on biotechnology, early cancer detection, mAb production, personalised medicine and diagnostic disciplines during the last 25 years. Dr. Moshiri has hosted numerous newscasts in preventive fields for National TV. In addition to his media expertise and bio-pharmaceutical marketing, his articles have been published in many American, European and Asian medical journals. He has been a contributing author of medical books published in North America. Dr. Moshiri has participated as an organizer, session chair, panelist, invited lecturer and keynote speaker in many World Medical Congresses. Dr. Moshiri has received four Medical World Congress and Innovation Awards.
Dr. Moshiri established a State-of-The-Art Medical Research Laboratory at Sunnybrook Research Center, (SRI-S4) (Toronto University, Ontario, Canada) and served as President, Director and Lead Scientist of the Research Laboratory that resulted to 75 patent inventions. In his Research Lab (S4) his scientific collaboration with other world class scientists of SRI, achieved him invaluable and indispensable practical experience along with many new patent-able discoveries on tumor markers and Aptamers from 2013 to 2016. Dr. Moshiri is trained as Medical Doctor and Clinical and Anatomical Pathologist and has been on faculty at several Medical Universities since 1988 to 2004 and have been in pharmaceutical industry since 2004 to present.

 Selected List of Consultants, Advisors, and Collaborators

Dan Dumont PhD , Sunnybrook Research Institute, Toronto University, Canada.
Eleftherios Diamandis MD , Mount Sinai Hospital, Toronto University, Canada.
Ru Li MD, PhD , Sunnybrook Research Institute, Toronto University, Canada.
Kiarash Moshiri MD, Next Pharma Inc., Toronto, Canada.

             Arsha Moshiri MD, Executive Vice President, Next Pharma Inc.                       
Eng. Saima Faruqui, Next Pharma Inc., Toronto, Canada.
Junaid Rahman MD, Don Bosco Hospital, Ernakulam District, Kerala, India.
Mary Joby George MSc. , Don Bosco Hospital, Ernakulam District, Kerala, India.
Siti Hajar Ibrahim MSc., Tropicana Medical Centre, Selangor, Malaysia.
Elena SeriKova PhD, N.N.N. Alexandrov National Cancer center, Minsk, Belarus.
Akasana Hatsko PhD, N.N.N. Alexandrov National Cancer center, Minsk, Belarus.
Elena Hapeyenka PhD, N.N.N. Alexandrov National Cancer center, Minsk, Belarus.
Oleg Sukonko MD, N.N.N. Alexandrov National Cancer center, Minsk, Belarus
Liliya Dzerzhavets PhD, N.N.N. Alexandrov National Cancer center, Minsk, Belarus
Reza Nazari PhD, Next Pharma Inc., Toronto, Canada.
Chris Sun PhD, Cloud Clone Corp, Wuhan, Hubei, China.
Yue Yinpu PhD, Cloud Clone Corp, Wuhan, Hubei, China.
Mehran Bakhteiari MS, Proteus Imaging Canada, Toronto, Canada.
H. Sekhavati PhD, Genetic Engineering and Animal Biotech. Lab., Mashhad University, Iran.
M.H. Monhemi PhD, Research and Technology Center of Biomolecules, MUMS, Iran.
Gholam Hossein Reiazi PhD, Institute of Biochemistry and Biophysics of Tehran University
Marzieh Dehghan PhD, Institute of Biochemistry and Biophysics of Tehran University.
Mahmood Moshiri MD, Next Pharma Inc., Toronto, Canada.

[/cs_text]